Trials / Not Yet Recruiting
Not Yet RecruitingNCT06697990
Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients
Exploring the Mechanism of Cerebrospinal Fluid Immune Microenvironment in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Lung Cancer With Brain Metastases Treated With Iruplinalib: an Interventional Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an an interventional study to explore the mechanism of cerebrospinal fluid immune microenvironment in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer with brain metastases treated with Iruplinalib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iruplinalib | 60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Source: ClinicalTrials.gov record NCT06697990. Inclusion in this directory is not an endorsement.